Correction to: DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network (Journal of Thrombosis and Thrombolysis, (2023), 55, 4, (685-690), 10.1007/s11239-023-02774-1)

Karlyn A. Martin*, Nicola Lancki, Celina Li, M. Elaine Eyster, Kristen Sanfilippo, Isabela A. Woller, Scott C. Woller, Lisa Baumann Kreuziger, Rachel P. Rosovsky

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

Journal of Thrombosis and Thrombolysis In the abstract of the original version of the article, the odds ratio for the 12-month recurrent VTE rate was incorrect and has been corrected in this version. In the original version of the article, the odds ratio was correctly reported in the results section of the main manuscript.

Original languageEnglish (US)
Pages (from-to)775
Number of pages1
JournalJournal of thrombosis and thrombolysis
Volume55
Issue number4
DOIs
StatePublished - May 2023

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Fingerprint

Dive into the research topics of 'Correction to: DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network (Journal of Thrombosis and Thrombolysis, (2023), 55, 4, (685-690), 10.1007/s11239-023-02774-1)'. Together they form a unique fingerprint.

Cite this